Comparable real‐world effectiveness between switches to cabotegravir + rilpivirine long‐acting or modern daily oral regimens in the United States: an OPERA cohort study
In the United States, routine clinical care, CVF risk did not differ between a switch to CAB+RPV LA or new oral ART, with most individuals remaining on their regimens at study end. Lower CD4 count at initiation was the only predictor of CVF on CAB+RPV LA.
Authors
- Michael Sension
- Jennifer S Fusco (ORCID: https://orcid.org/0000-0003-1556-811X)
- Jean van Wyk (ORCID: https://orcid.org/0000-0001-5719-7949)
- Michael Wohlfeiler
- Brooke Levis (ORCID: https://orcid.org/0000-0002-4310-3689)
- Quateka Cochran
- Laurence Brunet (ORCID: https://orcid.org/0000-0001-8467-4835)
- Vani Vannappagari (ORCID: https://orcid.org/0000-0002-0157-9689)
- Gregory Fusco (ORCID: https://orcid.org/0000-0002-6834-784X)
- Gayathri Sridhar
- Ricky K Hsu
Institutions
- AIDS Healthcare Foundation (US)
- Henderson Behavioral Health (US)
- NYU Langone Health (US)
- ViiV Healthcare (United Kingdom) (GB)
- GridBridge (United States) (US)
Publication Details
- Journal
- Journal of the International AIDS Society
- Published
- 2025-12-01
- DOI
- https://doi.org/10.1002/jia2.70068
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00